Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
[DOI] [PubMed] [Google Scholar] 72.ULC
Patients with a history of chronic pancreatitis, pancreatic cancer, or other significant pancreatic disorders may not be suitable candidates for this therapy
After the resolution of the deficiency, if patients show clinical or hematologic signs associated with polycythemia vera, it is recommended they undergo further evaluations
The body's preferred, natural form of B12